Hubei Guangji Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Hubei Guangji Pharmaceutical's earnings have been declining at an average annual rate of -45.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 1.4% per year.
Key information
-45.9%
Earnings growth rate
-47.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 1.4% |
| Return on equity | -12.1% |
| Net Margin | -18.3% |
| Next Earnings Update | 30 Aug 2024 |
Revenue & Expenses Breakdown
How Hubei Guangji Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 803 | -147 | 217 | 74 |
| 31 Dec 23 | 738 | -140 | 195 | 75 |
| 30 Sep 23 | 784 | -37 | 177 | 66 |
| 30 Jun 23 | 766 | 0 | 172 | 67 |
| 31 Mar 23 | 780 | -2 | 167 | 76 |
| 01 Jan 23 | 798 | 50 | 154 | 69 |
| 30 Sep 22 | 846 | 56 | 174 | 75 |
| 30 Jun 22 | 838 | 75 | 160 | 63 |
| 31 Mar 22 | 743 | 105 | 142 | 54 |
| 01 Jan 22 | 786 | 110 | 143 | 52 |
| 30 Sep 21 | 652 | 101 | 136 | 38 |
| 30 Jun 21 | 671 | 115 | 130 | 38 |
| 31 Mar 21 | 731 | 102 | 133 | 37 |
| 31 Dec 20 | 688 | 75 | 139 | 39 |
| 30 Sep 20 | 689 | 31 | 143 | 49 |
| 30 Jun 20 | 707 | 43 | 165 | 52 |
| 31 Mar 20 | 684 | 43 | 176 | 54 |
| 31 Dec 19 | 731 | 87 | 172 | 54 |
| 30 Sep 19 | 791 | 144 | 177 | 55 |
| 30 Jun 19 | 809 | 118 | 170 | 59 |
| 31 Mar 19 | 780 | 117 | 160 | 64 |
| 31 Dec 18 | 844 | 172 | 152 | 65 |
| 30 Sep 18 | 835 | 155 | 93 | 58 |
| 30 Jun 18 | 843 | 171 | 92 | 52 |
| 31 Mar 18 | 876 | 165 | 79 | 55 |
| 31 Dec 17 | 802 | 105 | 93 | 45 |
| 30 Sep 17 | 735 | 99 | 122 | 31 |
| 30 Jun 17 | 757 | 136 | 113 | 19 |
| 31 Mar 17 | 728 | 144 | 129 | 0 |
| 31 Dec 16 | 715 | 142 | 127 | 0 |
| 30 Sep 16 | 739 | 165 | 93 | 0 |
| 30 Jun 16 | 692 | 100 | 102 | 0 |
| 31 Mar 16 | 617 | 51 | 103 | 0 |
| 31 Dec 15 | 560 | 21 | 89 | 0 |
| 30 Sep 15 | 481 | -177 | 160 | 0 |
| 30 Jun 15 | 440 | -218 | 158 | 0 |
| 31 Mar 15 | 495 | -219 | 156 | 0 |
| 31 Dec 14 | 486 | -219 | 158 | 0 |
| 30 Sep 14 | 505 | -59 | 114 | 0 |
| 30 Jun 14 | 490 | -21 | 106 | 0 |
| 31 Mar 14 | 470 | 5 | 98 | 0 |
| 31 Dec 13 | 487 | 2 | 97 | 0 |
| 30 Sep 13 | 449 | -48 | 89 | 0 |
Quality Earnings: 000952 is currently unprofitable.
Growing Profit Margin: 000952 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000952 is unprofitable, and losses have increased over the past 5 years at a rate of 45.9% per year.
Accelerating Growth: Unable to compare 000952's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000952 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 000952 has a negative Return on Equity (-12.08%), as it is currently unprofitable.